BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38281232)

  • 1. Anticoagulant prescribing patterns in patients with primary central nervous system malignancies and secondary metastases.
    Abdelmessih E; Ahuja T; Wo S; Sango A; Papadopoulos J; Green D; Xiang E
    J Thromb Thrombolysis; 2024 Mar; 57(3):418-427. PubMed ID: 38281232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors.
    Carney BJ; Uhlmann EJ; Puligandla M; Mantia C; Weber GM; Neuberg DS; Zwicker JI
    J Thromb Haemost; 2019 Jan; 17(1):72-76. PubMed ID: 30450803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.
    Swartz AW; Drappatz J
    Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of intracranial hemorrhage with direct oral anticoagulation versus low molecular weight heparin in the treatment of brain tumor-associated venous thromboembolism: A meta-analysis.
    Yang J; He Z; Li M; Hong T; Ouyang T
    J Stroke Cerebrovasc Dis; 2023 Aug; 32(8):107243. PubMed ID: 37413715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study.
    Reed-Guy L; Desai AS; Phillips RE; Croteau D; Albright K; O'Neill M; Brem S; O'Rourke DM; Amankulor NM; Bagley SJ
    Neuro Oncol; 2022 Dec; 24(12):2172-2179. PubMed ID: 35551405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
    Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
    J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulation prescribing patterns in patients with cancer.
    Xiang E; Ahuja T; Raco V; Cirrone F; Green D; Papadopoulos J
    J Thromb Thrombolysis; 2018 Jan; 45(1):89-98. PubMed ID: 29052104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors.
    Lee A; Oley F; Lo M; Fong R; McGann M; Saunders I; Block S; Mahajan A; Pon TK
    Thromb Res; 2021 Dec; 208():148-155. PubMed ID: 34798446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases.
    Leader A; Hamulyák EN; Carney BJ; Avrahami M; Knip JJ; Rozenblatt S; Beenen LFM; Yust-Katz S; Icht O; Coppens M; Raanani P; Middeldorp S; Büller HR; Zwicker JI; Spectre G
    Blood Adv; 2020 Dec; 4(24):6291-6297. PubMed ID: 33351124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
    Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
    JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
    Gonzalez-Fajardo JA; Arreba E; Castrodeza J; Perez JL; Fernandez L; Agundez I; Mateo AM; Carrera S; Gutiérrez V; Vaquero C
    J Vasc Surg; 1999 Aug; 30(2):283-92. PubMed ID: 10436448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis.
    Cimminiello C; Prandoni P; Agnelli G; Di Minno G; Polo Friz H; Scaglione F; Boracchi P; Marano G; Harenberg J
    Intern Emerg Med; 2017 Dec; 12(8):1291-1305. PubMed ID: 28756546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-Analysis Comparing the Efficacy, Safety, and Cost-Benefit of Direct Acting Oral Anticoagulants Versus Enoxaparin Thromboprophylaxis to Prevent Venous Thromboembolism Among Hospitalized Patients.
    Bhalla V; Abdel-Latif A; Bhalla M; Ziada K; Williams MV; Smyth SS
    Am J Cardiol; 2018 Oct; 122(7):1236-1243. PubMed ID: 30082040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty.
    Wang TF; Grubic N; Carrier M; Canney M; Delluc A; Hundemer GL; Knoll G; Lazo-Langner A; Massicotte-Azarniouch D; Tanuseputro P; Sood MM
    Am J Hematol; 2023 Sep; 98(9):1374-1382. PubMed ID: 37340812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review.
    Iyengar V; Agrawal S; Chiasakul T; Tehranchi K; Mcnichol M; Carney BJ; Leader A; Zwicker JI; Patell R
    J Thromb Haemost; 2024 Feb; 22(2):423-429. PubMed ID: 37866517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness and safety of direct oral anticoagulants compared to conventional pharmacologic thromboprophylaxis in hip fracture patients: A systematic review and meta-analysis of randomized controlled trials.
    Abatzis-Papadopoulos M; Tigkiropoulos K; Nikas S; Papoutsis I; Kostopoulou O; Stavridis K; Karamanos D; Lazaridis I; Saratzis N
    Orthop Traumatol Surg Res; 2023 Apr; 109(2):103364. PubMed ID: 35817368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
    O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
    Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.
    Bazarbashi S; El Zawahry HM; Owaidah T; AlBader MA; Warsi A; Marashi M; Dawoud E; Jaafar H; Sholkamy SM; Haddad F; Cohen AT
    J Blood Med; 2024; 15():171-189. PubMed ID: 38686358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.
    Harrington J; Carnicelli AP; Hua K; Wallentin L; Patel MR; Hohnloser SH; Giugliano RP; Fox KAA; Hijazi Z; Lopes RD; Pokorney SD; Hong H; Granger CB
    Circulation; 2023 Jun; 147(23):1748-1757. PubMed ID: 37042255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.